Tilsotolimod
- Generic Name
- Tilsotolimod
- Brand Names
- -
- Drug Type
- Biotech
- Chemical Formula
- -
- CAS Number
- 1948266-37-2
- Unique Ingredient Identifier
- G287IC9MH3
- Background
Tilsotolimod is under investigation in clinical trial NCT03865082 (Study of Tilsotolimod in Combination With Nivolumab and Ipilimumab for the Treatment of Solid Tumors (ILLUMINATE-206)).
- Associated Conditions
- -
- Associated Therapies
- -
Intratumoral Tilsotolimod, a TLR-9 Agonist, Together With Intratumoral Ipilimumab and Intravenous Nivolumab in Patients With Advanced Cancers
- Conditions
- Interventions
- First Posted Date
- 2020-02-17
- Last Posted Date
- 2024-10-18
- Lead Sponsor
- Gustave Roussy, Cancer Campus, Grand Paris
- Target Recruit Count
- 25
- Registration Number
- NCT04270864
- Locations
- ๐ซ๐ท
Gustave Roussy, Villejuif, Val De Marne, France
A Study to Determine the Safety, Tolerability, Pharmacokinetics, and Preliminary Efficacy of ABBV-368 Plus Tilsotolimod and Other Therapy Combinations in Participants With Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma
- Conditions
- Interventions
- First Posted Date
- 2019-12-12
- Last Posted Date
- 2023-02-27
- Lead Sponsor
- AbbVie
- Target Recruit Count
- 30
- Registration Number
- NCT04196283
- Locations
- ๐บ๐ธ
The University of Chicago Medical Center /ID# 217196, Chicago, Illinois, United States
๐บ๐ธMD Anderson Cancer Center /ID# 214041, Houston, Texas, United States
๐บ๐ธNorton Cancer Institute /ID# 216179, Louisville, Kentucky, United States
A Randomized Controlled Phase II Trial With Intradermal IMO-2125 in Pathological Tumor Stage (p) T3-4 cN0M0 Melanoma
- Conditions
- Interventions
- First Posted Date
- 2019-10-15
- Last Posted Date
- 2021-04-15
- Lead Sponsor
- A.J.M. van den Eertwegh
- Target Recruit Count
- 214
- Registration Number
- NCT04126876
- Locations
- ๐ณ๐ฑ
VU Medical Centere, Amsterdam, Netherlands
Study of Tilsotolimod in Combination With Nivolumab and Ipilimumab for the Treatment of Solid Tumors (ILLUMINATE-206)
- Conditions
- Interventions
- First Posted Date
- 2019-03-06
- Last Posted Date
- 2022-02-17
- Lead Sponsor
- Idera Pharmaceuticals, Inc.
- Target Recruit Count
- 30
- Registration Number
- NCT03865082
- Locations
- ๐บ๐ธ
MD Anderson Cancer Center, Houston, Texas, United States
๐บ๐ธUniversity of Southern California/ Hoag Hospital Presbyterian, Newport Beach, California, United States
๐บ๐ธBanner University Medical Center Tucson Campus, Tucson, Arizona, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.